South Korea’s Ministry of Food and Drug Safety (MFDS) has given innovative medical device designation for Te Bios Co. Ltd.’s artificial cornea, C-Clear, bringing it one step closer to becoming the first artificial cornea to be approved in the country.
Antengene Corp. Ltd. has gained the first greenlight in Asia for the oral exportin 1 (XPO1) inhibitor selinexor, in-licensed from Karyopharm Therapeutics Inc., after South Korea’s Ministry of Food and Drug Safety gave the thumbs up for its NDA. The drug has been approved in Korea to treat relapsed or refractory multiple myeloma (MM) and relapsed and refractory diffuse large B-cell lymphoma (DLBCL) in combination with dexamethasone.
Zentera Therapeutics Inc. completed a $75 million series B financing round to help further its candidates in China, as it paves the way for a listing in Hong Kong next year.
Around 100,000 medical professionals have registered to learn breast cancer related information through Zhongchao Inc.’s Breast Cancer Tiered Diagnosis and Treatment Improvement Platform in the first half of 2021. It marks one of the earliest efforts conducted for the Healthy China 2030 Guidelines, which aims to increase the overall five-year cancer survival rate by 15% by 2030.
PERTH, Australia – Soft tissue regeneration company Aroa Biosurgery Ltd. completed a A$47 million (US$34.72 million) placement on the Australian Securities Exchange that will allow the company to accelerate and broaden its pipeline. What sets Auckland, New Zealand-based Aroa apart from other regenerative tissue companies is the rate of tissue regeneration with Aroa’s scaffold and its affordability, Aroa founder and CEO Brian Ward told BioWorld.
PERTH, Australia – After raising A$10 million (US$7.36 million) in its initial public offering on the Australian Securities Exchange, BCAL Diagnostics Ltd. is racing to commercialize its noninvasive, blood-based in vitro diagnostic to detect breast cancer. The Breast Cancer Associated Lipids (BCAL) test is taken via a blood sample and analyzed for lipid biomarkers.
Cell and gene therapy have seen much progress in recent times, with the product pipelines in those areas bursting with more than 1,200 therapies. Naturally, the challenges, opportunities and essential development strategies in those fields were the focus on the last day of the BIO Asia-Taiwan Conference 2021.
The biotech industry in Asia is a promising market, but it still has a long way to go to narrow the gap between Asian and Western markets, according to speakers on day two of the BIO Asia-Taiwan Conference 2021.
Financing is the fuel that drives growth in the biopharma sector, and participants at the BIO Asia-Taiwan Conference 2021 this week discussed different financing strategies for companies in the currently booming market.
Hongyun Biotech Co. Ltd. raised ¥100 million (US$15.5 million) in a series B round to move its new generation EGFR inhibitor, RC-01, to the IND stage in China and the U.S. for non-small-cell lung carcinoma (NSCLC). The plan is to finish the IND filing by the end of this year and start the trial in 2022.
RSS
